Drug Delivery Technologies Market: Market Size & Forecast 2026

The Drug Delivery Technologies Market encompasses the platforms, devices, and formulation approaches used to administer active pharmaceutical ingredients through routes such as oral, parenteral, transdermal, inhalation, and nasal. The market is valued at approximately $129.77 billion in 2025 and is projected to grow at around 11.02% annually through the end of the decade. North America currently leads in revenue share, while Asia-Pacific is emerging as the fastest-growing region due to expanding healthcare access and pharmaceutical manufacturing capacity.

• •Estimated global value of $129.77 billion in 2025 with ~11.02% CAGR
• •Covers oral, parenteral, transdermal, inhalation, and nasal delivery routes
• •North America leads in current revenue; Asia-Pacific is the fastest-growing region

Demand is being driven by the rising global burden of chronic conditions such as diabetes, cancer, and cardiovascular disease, which require long-term, often self-administered therapy. The shift toward biologics, monoclonal antibodies, and gene- and RNA-based therapies requires sophisticated delivery systems to protect fragile molecules and target specific tissues. Aging populations and increasing patient preference for minimally invasive, home-based treatment further accelerate adoption.

• •Rising prevalence of chronic and lifestyle-related diseases
• •Growth of biologics, biosimilars, and nucleic acid-based therapeutics
• •Aging populations and shift toward self-administration at home

By route of administration, the market is segmented into oral, parenteral, transdermal, inhalation, nasal, and others, with oral delivery historically dominant and parenteral delivery expanding quickly on the back of biologics. By therapeutic area, oncology, infectious diseases, central nervous system disorders, and diabetes/obesity represent the largest segments. Geographically, North America accounts for the largest share, followed by Europe, while Asia-Pacific is projected to grow at the highest rate through 2030.

• •Parenteral delivery is the fastest-growing route due to biologics and injectables
• •Oncology and diabetes/obesity are leading therapeutic applications
• •Asia-Pacific shows the highest projected regional growth rate

What are the recent trends and outlook?

Key trends include the rise of long-acting injectables, nanoparticle-based and lipid-based carriers for nucleic acid delivery, microneedle patches, and connected smart devices that support adherence monitoring. The GLP-1 receptor agonist boom in diabetes and obesity is reshaping demand for novel injectable and oral peptide delivery systems. With double-digit growth projected through the late 2020s, the market is expected to remain one of the most dynamic segments within the broader pharmaceutical industry.

• •Expansion of long-acting injectables, microneedles, and lipid nanoparticle platforms
• •GLP-1 agonists driving innovation in peptide and injectable delivery
• •Sustained double-digit growth expected through the end of the decade